Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Hisamitsu to Go Private in Management Buyout Valued at 400 Billion Yen
Japanese patch drug powerhouse Hisamitsu Pharmaceutical will go private through a management buyout, under which the company’s top management will acquire all outstanding shares and delist the drug maker from the Tokyo Stock Exchange. Under the transaction, announced late on…
To read the full story
Related Article
- Hisamitsu Sets April 17 Shareholders Meeting to Approve Squeeze-Out
March 16, 2026
- Hisamitsu Buyout Closed, Drug Maker Set to Go Private in May
February 24, 2026
- Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?
February 18, 2026
BUSINESS
- Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
- Women Hold Nearly 1/4 of Leadership Roles at Japan’s Listed Pharmas and Wholesalers
July 10, 2026
- Expert Welcomes Talvey-Tecvayli Combo for Difficult-to-Treat MM
July 10, 2026
- Axcelead Teams Up with Mitsubishi to Expand Drug Discovery Support Biz
July 10, 2026
- Roche PD-L1 Test Approved for Imfinzi in Endometrial Cancer
July 10, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…